Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Smith KK, Harris RS, Coffey M, Pulido JS, Pandha H, Selby PJ, Harrington KJ, Melcher A, Vile RG.
Evgin L, et al.
Cancer Immunol Res. 2019 May;7(5):828-840. doi: 10.1158/2326-6066.CIR-18-0013. Epub 2019 Apr 2.
Cancer Immunol Res. 2019.
PMID: 30940643
Free PMC article.